IL1B and neoplasm: The tumor-stroma-inflammation network identified in our study suggests that inhibiting the activities of TNBC-typical pro-inflammatory cytokines, such as TNFα and IL-1β would halt tumor-stroma interactions that stand in the basis of TNBC progression.